Evidence map›Paper›PMID 41799329›Full record

ArticleBJUI compass2026

EarlyTect BCD Plus: A urine-based dual site PENK methylation test for risk-based cystoscopy triage in haematuria.

Tae Jeong Oh, Bo-Ram Bang, Jae Hee Hwang, Yangyei Seo, Seoyong Kim, Sujin Gu, Safedin Beqaj, Theo deVos, Justin Junguek Lee, Jin Zhong and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BJUI compass, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Tae Jeong OhGenomictree, Inc. Daejeon Republic of Korea.
Bo-Ram BangPromis Diagnostics, Inc. Irvine California USA.
Jae Hee HwangGenomictree, Inc. Daejeon Republic of Korea.
Yangyei SeoGenomictree, Inc. Daejeon Republic of Korea.
Seoyong KimPromis Diagnostics, Inc. Irvine California USA.
Sujin GuPromis Diagnostics, Inc. Irvine California USA.
Safedin BeqajPromis Diagnostics, Inc. Irvine California USA.
Theo deVosPromis Diagnostics, Inc. Irvine California USA.ORCID https://orcid.org/0000-0003-2085-2844
Justin Junguek LeePromis Diagnostics, Inc. Irvine California USA.
Jin ZhongDepartment of Medicine University of California, Riverside Riverside California USA.
Joseph D ShirkDepartment of Urology VA Greater Los Angeles Medical Center Los Angeles California USA.
Katelyn W KePathology & Laboratory Medicine Service VA Greater Los Angeles Medical Center Los Angeles California USA.
John VallonePathology & Laboratory Medicine Service VA Greater Los Angeles Medical Center Los Angeles California USA.
Sungwhan AnGenomictree, Inc. Daejeon Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: This study aims to develop and clinically evaluate EarlyTect BCD Plus, a urine-based assay measuring two methylation sites of the Materials and Methods: A dual-target quantitative methylation-specific PCR assay was optimized using the Results: In the pooled cohort (gross haematuria, Conclusions: EarlyTect BCD Plus significantly enhances detection of Ta-LG bladder cancer while maintaining high specificity. Its high NPV supports use as a non-invasive adjunct and triage tool, allowing deferral of cystoscopy in selected haematuria patients.

Indexed as

biomarkershaematuriamolecular diagnostic techniquesproenkephalintumoururinary bladder neoplasms

Identifiers

PMID41799329
PMCPMC12966605

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.